Cost-effectiveness analysis of empagliflozin in the treatment of patients with type 2 diabetes and established cardiovascular disease in Italy, based on the results of the EMPA-REG OUTCOME study. FE. 2017;18(1). doi:10.7175/fe.v18i1.1332